Perspective Therapeutics (NYSE:CATX) Receives Buy Rating from B. Riley

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at B. Riley in a note issued to investors on Monday, Marketbeat Ratings reports. They currently have a $12.00 target price on the stock, up from their previous target price of $9.00. B. Riley's target price would indicate a potential upside of 231.49% from the company's current price. B. Riley also issued estimates for Perspective Therapeutics' Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.30) EPS.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald upgraded Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Scotiabank assumed coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 31st. Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Monday. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Perspective Therapeutics presently has an average rating of "Buy" and an average price target of $12.56.

Perspective Therapeutics Price Performance

CATX stock traded down $0.19 during trading hours on Monday, reaching $3.62. 1,133,535 shares of the stock were exchanged, compared to its average volume of 1,090,843. The firm's 50-day moving average is $2.75 and its 200-day moving average is $2.85. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $16.55.

Insider Buying and Selling

In other Perspective Therapeutics news, CFO Juan Graham acquired 33,333 shares of the company's stock in a transaction on Friday, March 28th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the purchase, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at approximately $79,546.50. This represents a 1,649.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert F. Williamson III acquired 38,145 shares of the business's stock in a transaction dated Monday, March 31st. The stock was acquired at an average cost of $2.14 per share, with a total value of $81,630.30. Following the completion of the transaction, the director now owns 108,982 shares of the company's stock, valued at approximately $233,221.48. The trade was a 53.85% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 115,696 shares of company stock worth $256,344. Insiders own 3.72% of the company's stock.

Institutional Investors Weigh In On Perspective Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC boosted its position in Perspective Therapeutics by 71.1% during the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company's stock worth $4,738,000 after purchasing an additional 924,196 shares during the period. MetLife Investment Management LLC lifted its stake in shares of Perspective Therapeutics by 40.9% during the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company's stock worth $67,000 after buying an additional 9,082 shares during the last quarter. HighTower Advisors LLC lifted its stake in shares of Perspective Therapeutics by 13.2% during the 1st quarter. HighTower Advisors LLC now owns 201,586 shares of the company's stock worth $429,000 after buying an additional 23,475 shares during the last quarter. Nuveen LLC bought a new stake in shares of Perspective Therapeutics during the 1st quarter worth about $2,647,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Perspective Therapeutics by 6.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 434,085 shares of the company's stock valued at $925,000 after buying an additional 27,119 shares during the last quarter. Institutional investors own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.